Figure 2.
Use of a potassium‐sparing diuretic in the hyperaldosteronism group at baseline and 1 year. Percentage of subjects in the hyperaldosteronism group who were being treated with a potassium‐sparing diuretic at baseline and 1 year. *P=.0009.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.